Rhythm Pharmaceuticals, Inc.

RYTM

$105.01

Name : Rhythm Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $7,007,953,408.00

EPSttm : -3.1

Rhythm Pharmaceuticals, Inc.

$105.01

1.90%

$2.03

Float Short %

8.95

Margin Of Safety %

Put/Call OI Ratio

0.63

EPS Next Q Diff

0.03

EPS Last/This Y

1.25

EPS This/Next Y

0.47

Price

104.97

Target Price

139

Analyst Recom

1.13

Performance Q

Relative Volume

0.53

Beta

2.01

Ticker: RYTM

17 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-08	RYTM	105.15	0.58	2.06	8235
2025-12-09	RYTM	100.71	0.56	2.00	8489
2025-12-10	RYTM	107.77	0.57	0.69	8505
2025-12-11	RYTM	117	0.56	0.07	8508
2025-12-12	RYTM	113.51	0.48	0.04	9576
2025-12-15	RYTM	112.54	0.44	0.00	10101
2025-12-16	RYTM	112.45	0.42	0.00	10430
2025-12-17	RYTM	111.85	0.44	0.04	10075
2025-12-18	RYTM	111.73	0.46	0.11	9847
2025-12-19	RYTM	112.05	0.47	0.12	9733
2025-12-22	RYTM	112.97	0.53	0.39	8399
2025-12-23	RYTM	112.36	0.54	0.00	8418
2025-12-26	RYTM	110.12	0.53	0.00	8428
2025-12-29	RYTM	112.58	0.59	0.00	7935
2025-12-30	RYTM	106.86	0.59	0.02	7948
2025-12-31	RYTM	107.15	0.59	0.03	7947
2026-01-02	RYTM	105.08	0.63	0.18	7718
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

17 items 1 of 1

17 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-08	RYTM	105.18	-4.6	-	-3.05
2025-12-09	RYTM	100.71	-4.6	-	-3.05
2025-12-10	RYTM	104.79	-4.6	-	-3.05
2025-12-11	RYTM	117.56	-4.6	-	-3.05
2025-12-12	RYTM	113.53	-4.6	-	-3.05
2025-12-15	RYTM	112.52	-4.6	-	-3.05
2025-12-16	RYTM	112.52	-4.6	-	-3.05
2025-12-17	RYTM	111.82	-4.6	-	-3.05
2025-12-18	RYTM	111.67	-8.5	-	-3.08
2025-12-19	RYTM	112.10	-8.5	-	-3.08
2025-12-22	RYTM	113.09	-8.5	-	-3.08
2025-12-23	RYTM	111.81	-8.5	-	-3.08
2025-12-26	RYTM	110.06	-9.0	-	-3.09
2025-12-29	RYTM	112.48	-9.0	-	-3.09
2025-12-30	RYTM	106.89	-9.0	-	-3.09
2025-12-31	RYTM	107.02	-9.0	-	-3.09
2026-01-02	RYTM	104.97	-9.0	-	-3.09
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

17 items 1 of 1

17 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-08	RYTM	-4.12	7.30	8.83
2025-12-09	RYTM	-4.12	7.30	8.83
2025-12-10	RYTM	-4.12	7.30	8.85
2025-12-11	RYTM	-3.97	7.30	8.85
2025-12-12	RYTM	-3.97	7.30	8.85
2025-12-15	RYTM	-4.00	7.30	8.85
2025-12-16	RYTM	-4.00	7.30	8.85
2025-12-17	RYTM	-4.00	7.30	8.85
2025-12-18	RYTM	-4.00	7.30	8.85
2025-12-19	RYTM	-4.00	7.30	8.85
2025-12-22	RYTM	-4.00	7.31	8.85
2025-12-23	RYTM	-4.00	7.31	8.85
2025-12-26	RYTM	-4.00	7.31	8.95
2025-12-29	RYTM	-4.00	7.31	8.95
2025-12-30	RYTM	-4.00	7.31	8.95
2025-12-31	RYTM	-4.00	7.31	8.95
2026-01-02	RYTM	-4.00	7.31	8.95
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

17 items 1 of 1

Last Quarter Act. EPS

-0.82

Avg. EPS Est. Current Quarter

-0.79

Avg. EPS Est. Next Quarter

-0.79

Insider Transactions

-4

Institutional Transactions

7.31

Beta

2.01

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

14.1

Max Drawdown 5-Year %

-92.1

Target Price

139

P/E

Forward P/E

PEG

P/S

40.2

P/B

47.05

P/Free Cash Flow

EPS

-3.1

Average EPS Est. Cur. Y

-3.09

EPS Next Y. (Est.)

-2.62

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-113.41

Relative Volume

0.53

Return on Equity vs Sector %

-94.1

Return on Equity vs Industry %

-78.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

Rhythm Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 283

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

stock quote shares RYTM – Rhythm Pharmaceuticals Inc. Stock Price stock today

news today RYTM – Rhythm Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RYTM – Rhythm Pharmaceuticals Inc. yahoo finance google finance

stock history RYTM – Rhythm Pharmaceuticals Inc. invest stock market

stock prices RYTM premarket after hours

ticker RYTM fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RYTM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y